Latest News - Aerie Pharmaceuticals

Friday, May 26, 2017 | Earnings & Financials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces Public Offering of Common Stock

Aerie Pharmaceuticals announced that it has commenced a registered underwritten public offering of $50 million of shares of its common stock. Cantor Fitzgerald & Co. is acting as the sole bookr…

Read the full story

Wednesday, May 24, 2017 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for Roclatan

Aerie Pharmaceuticals reported the successful primary efficacy results of the company’s 90-day, phase 3 Mercury 2 registration trial for its fixed-dose combination product candidate, Roclatan. T…

Read the full story

Monday, May 15, 2017 | Clinical Trials, Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa

Aerie Pharmaceuticals reported that it has received notification from the FDA that the agency has completed its initial 60-day review of the Rhopressa new drug application (NDA) and determined that th…

Read the full story

Wednesday, April 12, 2017 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Positive 6-Month Topline Safety and Efficacy Results for Rhopressa 0.02%

Aerie Pharmaceuticals reported the successful 6-month topline safety and efficacy results of its Rocket 4 phase 3 clinical trial for product candidate Rhopressa, a novel once-daily eye drop being test…

Read the full story

Monday, April 10, 2017 | Management/Leadership, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces Expansion of Commercialization Team

Aerie Pharmaceuticals announced the appointments of new employees Gary Menichini as Vice President of Sales, Dale Seibt as Vice President of Market Access, and Gerry McKenzie as Vice President of Comm…

Read the full story

Wednesday, March 08, 2017 | Earnings & Financials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Provides Update on Products in Development

As part of its fourth quarter and full-year earnings results reporting, Aerie Pharmaceuticals provided updates on several of its products in clinical development, including: Rhopressa (netarsud…

Read the full story

Wednesday, March 01, 2017 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces Resubmission of NDA for Rhopressa

Aerie Pharmaceuticals announced that it resubmitted its new drug application (NDA) for Rhopressa to the FDA after notification by its contract drug product manufacturer that the vendor’s Tampa, …

Read the full story

Tuesday, February 07, 2017 | Management/Leadership, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces Appointment of Huan Sheng, MD, PhD, as Director Clinical Research and Drug Safety

Aerie Pharmaceuticals announced the appointment of Huan Sheng, MD, PhD, as Director Clinical Research and Drug Safety, reporting to Kristine Erickson, OD, PhD, Aerie’s Vice President Clinical Re…

Read the full story

Monday, January 09, 2017 | Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Enters into Lease Agreement for New Manufacturing Plant in Ireland

Aerie Pharmaceuticals announced that it has entered into a lease agreement with the Industrial Development Agency (IDA) of Ireland for a new manufacturing plant in Athlone, Ireland. This will be Aerie…

Read the full story

Monday, December 26, 2016 | Miscellaneous, Aerie Pharmaceuticals

Aerie Pharmaceuticals Provides Update on Timing of NDA Filing for Rhopressa

Aerie Pharmaceuticals reported that it has been notified by its third party manufacturing vendor that the manufacturing line related to Rhopressa in their Tampa, Florida facility will not be ready for…

Read the full story

Tuesday, December 20, 2016 | Management/Leadership, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces Appointment of Judith J. Robertson as Chief Commercial Officer

Aerie Pharmaceuticals announced the appointment of Judith J. Robertson as Chief Commercial Officer, reporting to Thomas Mitro, Aerie President and Chief Operating Officer. Ms. Robertson will be respon…

Read the full story

Wednesday, December 07, 2016 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Completes Enrollment of Mercury 2 Phase 3 Registration Trial of Roclatan

Aerie Pharmaceuticals announced the completion of patient enrollment in the company’s second phase 3 registration trial (Mercury 2) of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%…

Read the full story

Thursday, October 27, 2016 | Clinical Trials, Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Positive Topline Efficacy Results of Rocket 4 Phase 3 Trial of Rhopressa

Aerie Pharmaceuticals reported the successful 90-day topline efficacy results of its Rocket 4 phase 3 clinical trial of product candidate Rhopressa, a novel once-daily eye drop being tested for its ab…

Read the full story

Friday, September 16, 2016 | Earnings & Financials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Raises $125 Million in Public Offerings

Aerie Pharmaceuticals announced the pricing of a registered underwritten public offering of $75 million of shares of its common stock at a price to the public of $29.50 per share, before deducting und…

Read the full story

Wednesday, September 07, 2016 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Submits New Drug Application to FDA for Rhopressa

Aerie Pharmaceuticals announced the submission of its new drug application (NDA) to the FDA for Rhopressa (netarsudil ophthalmic solution) 0.02%, according to a company news release. Rhopressa is a no…

Read the full story
Load More